First Trust Advisors LP Lowers Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

First Trust Advisors LP trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 32.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 311,785 shares of the biotechnology company's stock after selling 153,131 shares during the period. First Trust Advisors LP owned about 0.33% of Sarepta Therapeutics worth $37,910,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in SRPT. Capital International Ltd. CA boosted its holdings in shares of Sarepta Therapeutics by 31.0% in the fourth quarter. Capital International Ltd. CA now owns 18,430 shares of the biotechnology company's stock valued at $2,241,000 after purchasing an additional 4,357 shares during the period. Capital Group Investment Management PTE. LTD. lifted its holdings in shares of Sarepta Therapeutics by 30.2% in the 4th quarter. Capital Group Investment Management PTE. LTD. now owns 3,689 shares of the biotechnology company's stock worth $449,000 after buying an additional 856 shares during the period. Capital Group Private Client Services Inc. grew its position in shares of Sarepta Therapeutics by 95.8% during the 4th quarter. Capital Group Private Client Services Inc. now owns 119,218 shares of the biotechnology company's stock worth $14,496,000 after buying an additional 58,335 shares in the last quarter. Capital International Investors increased its stake in shares of Sarepta Therapeutics by 38.9% during the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after buying an additional 2,437,855 shares during the period. Finally, Capital International Sarl increased its stake in shares of Sarepta Therapeutics by 87.1% during the fourth quarter. Capital International Sarl now owns 35,256 shares of the biotechnology company's stock valued at $4,287,000 after buying an additional 16,408 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 7.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

SRPT has been the topic of several recent research reports. HC Wainwright reiterated a "neutral" rating and set a $75.00 target price on shares of Sarepta Therapeutics in a report on Wednesday, April 16th. Wells Fargo & Company assumed coverage on shares of Sarepta Therapeutics in a report on Friday, April 11th. They set an "overweight" rating and a $115.00 price objective on the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Piper Sandler reduced their price objective on shares of Sarepta Therapeutics from $182.00 to $110.00 and set an "overweight" rating for the company in a research note on Monday, April 21st. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research note on Wednesday, March 19th. Six analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Sarepta Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $158.70.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT traded up $1.55 during midday trading on Wednesday, reaching $62.40. The company's stock had a trading volume of 1,576,742 shares, compared to its average volume of 1,429,798. The firm has a market capitalization of $6.05 billion, a PE ratio of 49.92 and a beta of 0.93. The stock has a fifty day moving average of $74.58 and a 200 day moving average of $104.55. Sarepta Therapeutics, Inc. has a twelve month low of $48.01 and a twelve month high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.